June 9, 2025
In the News
Press Releases and Media Coverage
June 3, 2025
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
Read Article
April 14, 2025
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
Read Article
February 18, 2025
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
Read Article
December 2, 2024
The Bio Report Podcast: Getting Tumors to Say “Eat Me”
Read Article
November 8, 2024
The Cancer Letter: Preclinical Data Show Anti-CD24 Macrophage Checkpoint Inhibitor Promotes Phagocytosis and Shrinks Tumors
Read Article
November 7, 2024
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
Read Article
November 6, 2024
GEN: Parallel Platform Approach Slashes Process Development Time
Read Article
September 3, 2024
Drug Discovery Online: Does Targeting Macrophages Hold The Key For Treating Cancer?
Read Article
July 31, 2024